FDA clears eScreen's drugs-of-abuse test:
This article was originally published in Clinica
eScreen has received US FDA 510(k) clearance to market its automated, in-vitro drugs-of-abuse screening system, which the company claims is the first device for use in prescription workplace drug testing. The device provides a negative result within minutes, says the Overland Park, Kansas firm.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.